ANI Pharmaceuticals (Germany) Performance
| BSFA Stock | 52.50 1.00 1.94% |
The firm shows a Beta (market volatility) of -0.29, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning ANI Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, ANI Pharmaceuticals is likely to outperform the market. ANI Pharmaceuticals now shows a risk of 1.94%. Please confirm ANI Pharmaceuticals downside deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if ANI Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ANI Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, ANI Pharmaceuticals is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 12.9 M | |
| Total Cashflows From Investing Activities | -105.5 M |
ANI |
ANI Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 5,250 in ANI Pharmaceuticals on October 15, 2024 and sell it today you would earn a total of 0.00 from holding ANI Pharmaceuticals or generate 0.0% return on investment over 90 days. ANI Pharmaceuticals is generating 0.0185% of daily returns and assumes 1.9394% volatility on return distribution over the 90 days horizon. Simply put, 17% of stocks are less volatile than ANI, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
ANI Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ANI Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ANI Pharmaceuticals, and traders can use it to determine the average amount a ANI Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0095
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BSFA |
Estimated Market Risk
| 1.94 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ANI Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ANI Pharmaceuticals by adding ANI Pharmaceuticals to a well-diversified portfolio.
ANI Pharmaceuticals Fundamentals Growth
ANI Stock prices reflect investors' perceptions of the future prospects and financial health of ANI Pharmaceuticals, and ANI Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ANI Stock performance.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.0374 | |||
| Profit Margin | (0.24) % | |||
| Operating Margin | (0.13) % | |||
| Current Valuation | 894.88 M | |||
| Shares Outstanding | 17.45 M | |||
| Price To Book | 2.16 X | |||
| Price To Sales | 2.23 X | |||
| Revenue | 216.14 M | |||
| EBITDA | 3.12 M | |||
| Total Debt | 286.52 M | |||
| Book Value Per Share | 19.11 X | |||
| Cash Flow From Operations | 3.32 M | |||
| Earnings Per Share | (4.46) X | |||
| Total Asset | 771.6 M | |||
About ANI Pharmaceuticals Performance
Assessing ANI Pharmaceuticals' fundamental ratios provides investors with valuable insights into ANI Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the ANI Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about ANI Pharmaceuticals performance evaluation
Checking the ongoing alerts about ANI Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ANI Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 216.14 M. Net Loss for the year was (42.6 M) with profit before overhead, payroll, taxes, and interest of 117.43 M. | |
| Over 75.0% of the company shares are held by institutions such as insurance companies |
- Analyzing ANI Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ANI Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining ANI Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ANI Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ANI Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ANI Pharmaceuticals' stock. These opinions can provide insight into ANI Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.